{"transactions":[{"id":1428797,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-08-19T21:29:45.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":false,"shares":2969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":29688,"derivative":{"underlying":"Common Stock","underlying_shares":2969},"source":{"system":"sec-edgar","filing":"0000950170-24-098699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024098699/ownership.xml","form_type":"4"}},{"id":1428796,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-19T21:29:45.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":1128,"price":0.84,"value":947.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":77575,"source":{"system":"sec-edgar","filing":"0000950170-24-098699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024098699/ownership.xml","form_type":"4"}},{"id":1428795,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-19T21:29:45.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":true,"shares":2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":78703,"source":{"system":"sec-edgar","filing":"0000950170-24-098699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024098699/ownership.xml","form_type":"4"}},{"id":1510475,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-05-18T00:16:18.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":false,"shares":2968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":32657,"derivative":{"underlying":"Common Stock","underlying_shares":2968},"source":{"system":"sec-edgar","filing":"0000950170-24-062056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024062056/ownership.xml","form_type":"4"}},{"id":1510474,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-18T00:16:18.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1090,"price":0.94,"value":1024.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":75734,"source":{"system":"sec-edgar","filing":"0000950170-24-062056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024062056/ownership.xml","form_type":"4"}},{"id":1510473,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-18T00:16:18.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":true,"shares":2968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":76824,"source":{"system":"sec-edgar","filing":"0000950170-24-062056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024062056/ownership.xml","form_type":"4"}},{"id":1637501,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":false,"shares":11875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":35625,"derivative":{"underlying":"Common Stock","underlying_shares":11875},"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1637500,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":31250,"derivative":{"underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1637499,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":287905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively."}],"balance_after":287905,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":287905},"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1637498,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":187500,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1637497,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":5010,"price":1.08,"value":5410.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":73856,"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1637496,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-17T02:15:49.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":true,"shares":11875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":78866,"source":{"system":"sec-edgar","filing":"0000950170-24-016688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024016688/ownership.xml","form_type":"4"}},{"id":1753004,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:39:07.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":false,"shares":11361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":11360,"derivative":{"underlying":"Common Stock","underlying_shares":11361},"source":{"system":"sec-edgar","filing":"0000899243-23-020075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020075/doc4.xml","form_type":"4"}},{"id":1753003,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:39:07.000Z","date":"2023-04-27","kind":"grant","planned":true,"acquired":true,"shares":22721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":22721,"derivative":{"underlying":"Common Stock","underlying_shares":22721},"source":{"system":"sec-edgar","filing":"0000899243-23-020075","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020075/doc4.xml","form_type":"4"}},{"id":1753002,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:39:07.000Z","date":"2023-10-30","kind":"sale","planned":true,"acquired":false,"shares":4066,"price":1.35,"value":5489.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":66991,"source":{"system":"sec-edgar","filing":"0000899243-23-020075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020075/doc4.xml","form_type":"4"}},{"id":1753001,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:39:07.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":true,"shares":11361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."}],"balance_after":71057,"source":{"system":"sec-edgar","filing":"0000899243-23-020075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020075/doc4.xml","form_type":"4"}},{"id":1909939,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common stock","published_at":"2023-05-01T20:46:25.000Z","date":"2023-04-28","kind":"sale","planned":false,"acquired":false,"shares":7038,"price":5.19,"value":36527.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":59696,"source":{"system":"sec-edgar","filing":"0000899243-23-011945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323011945/doc4.xml","form_type":"4"}},{"id":1909938,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common stock","published_at":"2023-05-01T20:46:25.000Z","date":"2023-04-27","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares."}],"balance_after":66734,"source":{"system":"sec-edgar","filing":"0000899243-23-011945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323011945/doc4.xml","form_type":"4"}},{"id":2027996,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T22:50:49.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":95000,"derivative":{"exercise_price":5.5,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000899243-23-004211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323004211/doc4.xml","form_type":"4"}},{"id":2027995,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-02-07T22:50:49.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."}],"balance_after":47500,"derivative":{"underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000899243-23-004211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323004211/doc4.xml","form_type":"4"}},{"id":2129343,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common stock","published_at":"2022-10-31T23:37:25.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":5012,"price":7.93,"value":39745.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":46734,"source":{"system":"sec-edgar","filing":"0000899243-22-034598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322034598/doc4.xml","form_type":"4"}},{"id":2129342,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common stock","published_at":"2022-10-31T23:37:25.000Z","date":"2022-10-27","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 20,000 shares."}],"balance_after":51746,"source":{"system":"sec-edgar","filing":"0000899243-22-034598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322034598/doc4.xml","form_type":"4"}},{"id":2211307,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2022-07-06T23:22:52.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"balance_after":31746,"source":{"system":"sec-edgar","filing":"0000899243-22-025514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322025514/doc4.xml","form_type":"4"}},{"id":2407853,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-09T02:30:53.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":175000,"derivative":{"exercise_price":7.38,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000899243-22-005320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322005320/doc4.xml","form_type":"4"}},{"id":3001919,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":88219,"kind":"person","name":"Ege David S.","position":1,"cik":"0001829360","reported_name":"Ege David S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-21T21:02:28.000Z","date":"2020-10-19","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on October 19, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":32.6,"expiration_date":"2030-10-18","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-20-028909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924320028909/doc4.xml","form_type":"4"}}]}